Jaguar Health, Inc. (JAGX)
JAGXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.4281
+0.0238 (+5.89%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $5.82m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.3600 to $1,102.36
- Average volume
- 2.88m
- Previous close
- $0.4043
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $3.08m | $3.23m | $20.27m | $1.23m |
| Gross profit | $2.55m | $1.03m | $19.11m | $194.0k |
| Operating income | -$7.24m | -$21.24m | $10.18m | -$7.60m |
| Net income | -$9.50m | -$23.06m | $8.85m | -$12.68m |
Last four quarters: revenue $27.82m, margin -130.8%, free cash flow –
News
8 latest- Jaguar Health, Inc. Stockholders Approve Reverse Stock Split and Warrant Repricing at November 6, 2026 Special MeetingFintel · 3 days ago
- Jaguar Health, Inc. Announces Automatic Conversion of Series R Convertible Preferred StockFintel · 6 days ago
- Jaguar Health, Inc. Announces Share Reserve Adjustment to 2014 Stock Incentive PlanFintel · Oct 29, 2026
- Jaguar Health Shares Jump As Napo Showcases Intestinal Failure Program At Abu Dhabi Conference RTTNews · Oct 6, 2026
- 5 Biotech Stocks Making Headlines - ADRX, CNSY, JAGX, AGL, ONCO RTTNews · Sep 25, 2026
- Jaguar Health Plunges After Tuesday Rally; Reverse Stock Split And FDA Fee Waivers In Focus RTTNews · Sep 23, 2026
- Jaguar Health (JAGX) Q3 2025 Earnings TranscriptThe Motley Fool · May 21, 2026
- Jaguar Health Reports Q1 2026 Revenue Surge Driven By Licensing Deal RTTNews · May 21, 2026
The company
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals, Inc. (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- jaguar.health
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.